Iambic Therapeutics Reports Q3 Revenue Beat Amid Significant Earnings Miss
Iambic Therapeutics (IAM) reported third-quarter financial results characterized by a substantial earnings miss alongside strong revenue growth. The company posted a GAAP EPS of -$8.52, missing analyst expectations by $7.75. However, collaboration revenue reached $11.4 million, representing a 142.6% increase year-over-year and exceeding estimates by $3.11 million. As of September 30, 2026, the company maintained a strong liquidity position with $252 million in cash and cash equivalents, excluding proceeds from its initial public offering. While the revenue beat highlights successful collaboration efforts, the significant earnings deficit reflects ongoing high operational costs typical of the biotechnology sector.

Tickers: $IAM
Topics: cash position collaboration revenue earnings miss revenue beat